Radiolabeled alphaVbeta3 and SSTR2 double-targeting complex and application thereof

By developing radiolabeled αVβ3 and SSTR2 dual-targeting complexes, combining αVβ3 and SSTR2 targeting groups, the problems of deletion of SSTR2 expression and high physiological uptake of the kidneys in high-level NETs were solved, and the tumor detection rate and therapeutic effect were improved , achieving higher specificity and sensitivity.

CN119019501APending Publication Date: 2024-11-26PEKING UNION MEDICAL COLLEGE HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410920593.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing radionuclide-targeting compounds are insufficient in detection rates and treatment effects caused by deletion of SSTR2 expression and high physiological uptake of the kidney in high-grade neuroendocrine tumors, especially in the detection and treatment of lesions of high-grade NET and its metastatic lesions. middle.

Method used

Develop a radiolabeled αVβ3 and SSTR2 dual-targeting complex that improves affinity and specificity for αVβ3 and SSTR2 and reduces renal uptake by binding to αVβ3 and SSTR2 targeting groups, and is used for imaging and PRRT of high-level NET treat.

Benefits of technology

It improves the detection rate and treatment effect of high-grade NET and its metastatic lesions, reduces renal uptake, enhances tumor specificity, improves the sensitivity of PET/CT imaging and the efficacy of PRRT.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019501A_ABST
    Figure CN119019501A_ABST
Patent Text Reader

Abstract

The invention discloses a radiolabeled alpha V beta 3 and SSTR2 double-targeting complex and application thereof, and belongs to the technical field of radiopharmaceuticals and nuclear medicine diagnosis and treatment. The general formula of the radiolabeled alpha V beta 3 and SSTR2 double-targeting complex is as shown in the figure # imgabs0 #, L1 is a linking group connected with an integrin receptor, L2 is a linking group between L2 and an SSTR2 targeting group, L3 is a linking group between L3 and a chelating group or a chelating structure of chelating radionuclide, Peptide is a polypeptide molecule with SSTR2 targeting, such as JR11, LM3, LM4, TATE, TOC, NOC, etc. And the Chenator is a chelating agent or a chelating structure. The radiolabeled alpha V beta 3 and SSTR2 double-targeting complex contains different chelating agents, can be chelated with almost all current clinical radioactive diagnosis and treatment metal nuclides, including nuclides such as < 68 > Ga, [< 18 > F] AlF, < 44 > Sc and < 64 > Cu for emitting beta + rays for diagnosis; the radionuclides, such as 177Lu and 90Y, are used for emitting beta-rays for treatment; and emitting alpha rays for nuclides such as 225Ac, 212 / 213Bi and the like for treatment. The method is helpful to improve the focus detection rate of high-level NET, realizes more accurate tumor staging and disease prognosis, and is expected to be used for radionuclide targeted therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel radioactive nuclide labeled complex and its application, and in particular to a radioactive labeled α V The β3 and SSTR2 dual-targeting complex and application thereof belong to the field of radiopharmaceutical chemistry and nuclear medicine diagnosis and treatment technology. Background Art

[0002] Neuroendocrine tumors (NETs) are a class of rare tumors that are highly heterogeneous and arise from peptide neurons and neuroendocrine cells. Approximately 70% of NETs form in the gastrointestinal pancreatic system, 25% form in the respiratory system, and 5% form in other organs. According to the WHO grading system, NETs are further subdivided into three grades based on pathological characteristics: low-grade, well-differentiated, and possibly benign NETs (G1, Ki-67 <2%); moderately differentiated NETs with uncertain behavior (G2, Ki-67 3%-20%); and poorly differentiated, highly malignant NETs (G3, Ki-67>20%). Most well-differentiated NETs (G1 or G2) are usually characterized by highly overexpressed SSTR2 (somatostatin receptor 2), making SSTR2 a cellular target for diagnostic and therapeutic radiopharmaceuticals. [ 111 In]In / [ 99m Tc]Tc-HYNIC-TOC scintigraphy are the two most widely used tools in the diagnosis of NETs. 68 Ga]Ga-DOTATE(NETSPOT),[ 68 Ga]Ga-DOTATOC (Ga-68 DOTATOC) and [ 177 Lu]Lu-DOTATATE (LUTATHERA) is approved by the FDA for the detection of SSTR2-positive NETs or PRRT (peptide receptor-radionuclide therapy). Some drugs based on SSTR2 antagonists, such as [ 68 Ga]Ga-NODAGA-LM3 and [ 68 Ga]Ga-NODAGA-JR11, was also evaluated in NET patients and further developed as a PRRT agent. However, when tumors become more differentiated and invasive, SSTR expression is reduced or absent. 68 In SSTR2 imaging such as Ga]Ga-DOTATE PET / CT, the higher the tumor grade, the lower the average SUV (standardized uptake value), which may reduce the detection rate of lesions. In such patients, SSTR2-based PRRT may not be applicable.

[0003] Integrin α Vβ3 is significantly upregulated in activated endothelial cells, and its expression reflects not only tumor invasion and metastasis, but also angiogenesis. NET is one of the most extensively vascularized tumors, and different degrees of α V β3 is also present on the surface of tumor cells. 68 A phase II prospective study of α Ga]Ga-NODAGA-E[c(RGDyK)]2PET / CT showed that V β3 is expressed in both low-grade and high-grade NETs, ​​and patients with higher radiotracer uptake in tumor lesions have a higher risk of disease progression.

[0004] In recent years, the method of combining specific peptides with different receptor targeting properties into a heterodimeric radioligand to improve tumor targeting has been widely studied. V Heterobivalent ligands that dual-target β3 and SSTR2 are expected to overcome the problem of missing SSTR2 expression in high-grade NETs. By labeling different diagnostic and therapeutic radionuclides, it will be beneficial to the lesion detection rate and treatment effect of high-grade NETs and their metastases.

[0005] This research team has previously developed a method that simultaneously targets α V Heterodimer of β3 and SSTR2 68 Ga]Ga-NOTA-3PEG4-TATE-RGD, due to the higher T / B ratio, [ 68 Ga]Ga-NOTA-3PEG4-TATE-RGD is more effective in detecting NET liver metastasis than [ 68 Ga]Ga-DOTATE; and in the high expression of α V The T / B ratio in non-small cell lung cancer of β3 was significantly higher than that of 68 Ga]Ga-NOTA-TATE and [ 68 Ga]Ga-NOTA-RGD overcomes the shortcomings of single-target tracers in the evaluation of lung cancer.

[0006] However, due to the kidney's 68 The high physiological uptake of Ga]Ga-NOTA-3PEG4-TATE-RGD, the overflow and extravasation signals in the kidneys may seriously affect the quantification of radioactivity levels in adjacent lesions of the gastrointestinal pancreatic system, and the α V The development of PRRT-targeted compounds targeting β3 and SSTR2 is also limited.

[0007] Therefore, a new type of radioactive dual-targeting complex is provided, which has better α V The ability to target β3 and SSTR2, while having good in vivo biological metabolism properties and low renal uptake, has become a technical challenge that urgently needs to be solved in this technical field. Summary of the invention

[0008] One of the objects of the present invention is to provide a radiolabeled α V β3 and SSTR2 dual-targeting complex, which showed V The high affinity and specificity of β3 and SSTR2 will help solve the problem of limited tumor visualization sensitivity caused by differences in receptor expression on different prostate cancer lesions. At the same time, the introduction of SSTR2 targeting groups will help improve the lesion detection rate of high-grade NETs and their metastases, and is expected to be used for radionuclide targeted therapy.

[0009] The above object of the present invention is achieved through the following technical solutions:

[0010] A radiolabeled alpha V β3 and SSTR2 dual-targeting complex, the general formula is as follows:

[0011]

[0012] Wherein, Chelator is a chelating group or a chelating structure for chelating radioactive nuclides, selected from any one of the following:

[0013]

[0014] Among them, M includes but is not limited to 68 Ga, 18 F-AlF, 177 Lu, 90 Y. 44 Sc, 225 Ac, 212 Pb, 213 Bi et al;

[0015] L1 is a linker group connected to the integrin receptor, selected from any of the following:

[0016]

[0017] Wherein, n is an integer from 1 to 6;

[0018] L2 is a connecting group between the SSTR2 targeting group and is selected from any one of the following:

[0019]

[0020] Wherein, n is an integer from 1 to 6;

[0021] L3 is a connecting group with the chelating group or the chelating structure of the chelated radionuclide, selected from any one of the following:

[0022]

[0023] Wherein, n is an integer from 1 to 6;

[0024] Peptide is a SSTR2 targeting group, selected from any one of the following: JR11, LM3, LM4, TATE, TOC, NOC, etc., with the following structure:

[0025]

[0026] Preferably, the radiolabeled α V The specific structure of the β3 and SSTR2 dual-targeting complex is as follows:

[0027]

[0028] M= 68 Ga or 177 Lu, [ 68 Ga / 177 Lu]-DOTA-TATE-RGD

[0029]

[0030] [ 68 Ga]Ga-NOTA-TOC-RGD

[0031] Another object of the present invention is to provide the above radiolabeled α V Application of β3 and SSTR2 dual-targeting complexes in high-grade NET imaging and radionuclide diagnosis.

[0032] The above object of the present invention is achieved through the following technical solutions:

[0033] Radiolabeled α V Application of β3 and SSTR2 dual-targeting complexes in high-grade NET imaging and radionuclide diagnosis, as α V β3 and SSTR2 dual-targeting PET imaging agents can have higher uptake in high-grade NETs, ​​thereby improving the tumor detection rate of PET / CT imaging.

[0034] Radiolabeled α V The application of β3 and SSTR2 dual-targeting complexes in the preparation of PRRT drugs, labeled with radioactive therapeutic nuclides, is used for PRRT treatment of high-grade NETs.

[0035] Beneficial effects:

[0036] The radiolabeled α V β3 and SSTR2 dual-targeting complexes show targeting of integrin receptor α Vβ3 and somatostatin receptor SSTR2 have high affinity and specificity, and have good biological metabolism properties in vivo, making them the most promising α V β3 and SSTR2 dual-targeting PET imaging agents or PRRT drugs can be used for high-level NET imaging and PRRT treatment.

[0037] The present invention is further described below through the accompanying drawings and specific implementation modes, but it is not intended to limit the protection scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The mass spectrum of DOTA-TATE-RGD prepared in Example 1 of the present invention is characterized by a theoretical value of m / z of 2866.21 and an actual value of [M+2H] 2+ 1434.74, [M+3H] 3+ 956.78, [M+4H] 4+ 717.75;

[0039] Figure 2 The mass spectrum of NOTA-TOC-RGD prepared in Example 2 of the present invention is characterized by a theoretical value of m / z of 2916.33 and an actual value of [M+2H] 2+ 1459.77, [M+3H] 3+ 973.47;

[0040] Figure 3 [ 68 Radioactive HPLC spectrum of the labeling reaction solution of Ga]Ga-DOTA-TATE-RGD;

[0041] Figure 4 [ 177 Radioactive HPLC spectrum of the labeling reaction solution of Lu]Lu-DOTA-TATE-RGD;

[0042] Figure 5 [ 68 Radioactive HPLC spectrum of the labeling reaction solution of Ga]Ga-NOTA-TOC-RGD;

[0043] Figure 6 In the application example 1 of the present invention, in vitro A549 cells uptake [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68Ga]Ga-DOTA-RGDyk uptake-time curve (n=3);

[0044] Figure 7 In the application example 2 of the present invention, HEK293-SSTR2 cells in vitro uptake [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTATATE uptake-time curve (n=3);

[0045] Figure 8 In Example 3 of the present invention, the biodistribution experiment was performed to analyze the injection of 68 Ga]Ga-DOTA-TATE-RGD, [ 68 The uptake of Ga]Ga-NOTA-TOC-RGD in the main metabolic organs and tumors of A549 and H69 tumor-bearing mice after 60 minutes was similar to that of [ 68 Ga]Ga-NOTA-3PEG4-TATE-RGD for comparison;

[0046] Fig. 9 In the application example 4 of the present invention, injection [ 68 Ga]Ga-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTA-RGDyk, [ 68 Small animal PET imaging results in mice bearing A549 and H69 tumors after 60 minutes of treatment with Ga]Ga-DOTATATE. DETAILED DESCRIPTION

[0047] Unless otherwise specified, the reagents and raw materials used in the preparation methods and detection methods described in the following examples and comparative examples are all commercially available products, and the equipment used is all commonly used equipment; the concentrations and ratios described are all weight units.

[0048] The drugs used in preparing DOTA-TATE-RGD and NOTA-TOC-RGD in Examples 1 and 2 of the present invention are shown in Table 1 below:

[0049] Table 1

[0050]

[0051] Example 1: Preparation of DOTA-TATE-RGD

[0052]

[0053] 6 mmol CTC Resin was added, and PyBOP (3.0 eq) / DIEA (6.0 eq) was used for condensation, and then 4,7,10,13-tetraoxahexadecanedioic acid, Fmoc-Lys-OAll, Fmoc-D-Tyr-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH and Fmoc-Arg(Pbf)-OH were added in sequence, and the Fmoc protecting group was removed by 20% Pip / DMF, and the All protecting group was removed by Pb / triisopropylsilane system, and the ring was further closed, and 1% TFA / DCM was used for cleavage 4 times, and flash purification was performed to obtain compound 1;

[0054] 3 mmol CTC Resin was added, and PyBOP (3.0 eq) / DIEA (6.0 eq) was used for condensation. Fmoc-Thr(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Thr(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Trt)-OH and Fmoc-D-Phe-OH were added in sequence. The Fmoc protecting group was removed using 20% ​​Pip / DMF. After the solid phase synthesis of the peptide chain was completed, 30 mL of cutting solution (87.5% TFA / 7.5% DTT / 2.5% TIS / 2.5% H2O), react for 3h, filter to obtain the filtrate, add dropwise to tert-methyl ether to precipitate the solid, dissolve the crude product in 600mL of ACN / H2O (1:1) solution, add 2mL of 1% I2 / MeOH, stir to react for 1h, LCMS detection shows that the reaction is complete, freeze-dry, and flash-purify to obtain white powder compound 2;

[0055] 2 mmol CTC Resin was added, and PyBOP (3.0 eq) / DIEA (6.0 eq) was used for condensation. Fmoc-NH-PEG4-CH2CH2COOH, Fmoc-Glu(Dde)-OH, and Fmoc-NH-PEG4-CH2CH2-COOH were added in sequence to remove Dde. Fmoc-Cl was added, and the mixture was cut with 1% TFA / DCM for 4 times. The filtrate was concentrated and flash purified to obtain compound 3.

[0056] Compound 2 (50 μmol), compound 3 (42 μmol) and PyBOP (26 mg; 50 μmol) were dissolved in DMF (0.5 mL), DIEA (16 mg; 126 μmol) was added, and the mixture was stirred for 1 h. After the reaction was completed by LCMS, the reaction solution was added dropwise to tert-methyl ether to precipitate a solid. 1 mL of 20% Pip / DMF was added, and the mixture was stirred for 30 min. Compound 4 was obtained by flash purification.

[0057] Compound 1 (24 μmol), compound 4 (19 μmol) and PyBOP (12.5 mg; 50 μmol) were dissolved in DMF (0.5 mL), DIEA (7.5 mg; 57 μmol) was added, and the mixture was stirred for 1 h. The reaction was completed by LCMS. The reaction solution was added dropwise to methyl tert-ether to precipitate a solid. 1 mL of cutting solution (87.5% TFA / 7.5% DTT / 2.5% TIS / 2.5% H2O) was added and the mixture was reacted for 3 h. The filtrate was filtered to obtain a filtrate, which was added dropwise to methyl tert-ether to precipitate a solid. The crude product was dissolved in 1 mL of 5% hydrazine hydrate / DMF solution and stirred for 30 min. The reaction was completed by LCMS. After flash purification and freeze-drying, a white powder compound 5 was obtained.

[0058] Compound 5 (410 μmol) and carboxyl-activated bifunctional chelator DOTA (18 μmol) were added to 1 mL of DMF to dissolve, and then DIEA (8 μL, 48 μmol) was added and stirred for 1 h. LCMS was used to detect the product until the product was generated and compound 5 was completely consumed. 250 μL of piperidine was added to the reaction solution and stirring was continued for 30 min. LCMS was used to detect the final product DOTA-TATE-RGD after preparation and purification.

[0059] DOTA-TATE-RGD was characterized by mass spectrometry: the theoretical value m / z was 2866.21, the measured value [M+2H] 2+ 1434.74, [M+3H] 3+ 956.78, [M+4H] 4+ 717.75, such as Figure 1 shown.

[0060] Example 2: Preparation of NOTA-TOC-RGD

[0061]

[0062] The synthesis methods of compounds 1 and 3 are the same as above;

[0063] 3 mmol CTC Resin was added, and PyBOP (3.0 eq) / DIEA (6.0 eq) was used for condensation. Fmoc-Thr(OtBu)-OL, Fmoc-Cys(Trt)-OH, Fmoc-Thr(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Trt)-OH and Fmoc-D-Phe-OH were added in sequence. The Fmoc protecting group was removed using 20% ​​Pip / DMF. After the solid phase synthesis of the peptide chain was completed, 30 mL of cutting solution (87.5% TFA / 7.5% DTT / 2.5% TIS / 2.5% H2O) for 3 h, filtered to obtain a filtrate, which was added dropwise to tert-methyl ether to precipitate a solid. The crude product was dissolved in 600 mL of ACN / H2O (1:1) solution, and 2 mL of 1% I2 / MeOH was added and stirred for 1 h. The reaction was completed by LCMS detection, and the mixture was lyophilized and flash purified to obtain a white powder compound 6;

[0064] Compound 6 (50 μmol), compound 3 (40 μmol) and PyBOP (26 mg; 50 μmol) were dissolved in DMF (0.5 mL), DIEA (16 mg; 126 μmol) was added, and the mixture was stirred for 1 h. After the reaction was completed by LCMS, the reaction solution was added dropwise to tert-methyl ether to precipitate a solid, 1 mL of 20% Pip / DMF was added, and the mixture was stirred for 30 min. Compound 7 was obtained by flash purification.

[0065] Compound 1 (25 μmol), compound 7 (20 μmol) and PyBOP (12.5 mg; 50 μmol) were dissolved in DMF (0.5 mL), DIEA (7.5 mg; 57 μmol) was added, and the mixture was stirred for 1 h. The reaction was completed by LCMS. The reaction solution was added dropwise to methyl tert-ether to precipitate a solid. 1 mL of cutting solution (87.5% TFA / 7.5% DTT / 2.5% TIS / 2.5% H2O) was added and the mixture was reacted for 3 h. The mixture was filtered to obtain a filtrate, which was added dropwise to methyl tert-ether to precipitate a solid. The crude product was dissolved in 1 mL of 5% hydrazine hydrate / DMF solution, and the mixture was stirred for 30 min. The reaction was completed by LCMS. The compound 8 was flash purified and freeze-dried to obtain a white powder.

[0066] Compound 8 (12 μmol) and NOTA-NCS (20 μmol) were added together into 1 mL of DMF to dissolve, and then DIEA (8.01 μL, 48.52 μmol) was added and stirred for 1 h. LCMS detected that the product was generated and compound 8 was completely consumed. 250 μL of piperidine was added to the reaction solution and stirring was continued for 20 min. LCMS detection was performed and the final product NOTA-TOC-RGD was obtained after preparation and purification.

[0067] NOTA-TOC-RGD was characterized by mass spectrometry: the theoretical value m / z was 2916.33, the measured value [M+2H] 2+ 1459.77, [M+3H] 3+ 973.47; Figure 2 shown.

[0068] Example 3: 68 Preparation of Ga]Ga-DOTA-TATE-RGD

[0069] A pure aqueous solution (1 mg / mL) containing 10 nmol of DOTA-TATE-RGD was mixed with 93 μL of 1.25 M sodium acetate solution to obtain a radioligand sodium acetate mixed solution; a germanium gallium generator (Eckert & Ziegler, 1850 MBq, 50 mCi) was eluted with 5 mL of 0.1 M high-purity hydrochloric acid solution to obtain [ 68 Ga]GaCl3 hydrochloric acid solution, take 1mL, add it to the radioligand sodium acetate mixed solution, mix well, react at 90℃ for 10min, cool to room temperature, purify with C18 column, and determine its radiochemical purity with radio-HPLC to obtain [ 68 Ga]Ga-DOTA-TATE-RGD;

[0070] like Figure 3 As shown, the [ 68 The radioactive HPLC spectrum of the labeled reaction solution of Ga]Ga-DOTA-TATE-RGD shows that [ 68 The radiochemical purity of Ga]Ga-DOTA-TATE-RGD is greater than 95%;

[0071] In the above steps, in the C18 column purification, 10 mL of ethanol and 10 mL of water are used to activate the C18 column. After the reaction solution is loaded onto the column, the column is rinsed with 10 mL of water and 0.3 mL of ethanol is used to elute the column to obtain the product;

[0072] In the above steps, in the radio-HPLC determination, the first mobile phase is an aqueous solution of 0.1% trifluoroacetic acid, the second mobile phase is acetonitrile, and the gradient elution conditions are: 0 min, 95% of the first mobile phase; 0 to 20 min, 95% to 0% of the first mobile phase; the flow rate of the mobile phase is 1 mL / min.

[0073] Example 4: 177 Preparation of Lu]Lu-DOTA-TATE-RGD

[0074] A pure aqueous solution (1 mg / mL) containing 10 nmol DOTA-TATE-RGD was mixed with 200 μL of 1.25 M sodium acetate solution to obtain a radioligand sodium acetate mixed solution; [ 177 Lu]LuCl3 was added to the radioligand sodium acetate mixed solution, mixed evenly, reacted at 90°C for 30 min, cooled to room temperature, and its radiochemical purity was determined by radio-HPLC to obtain [ 177 Lu]Lu-DOTA-TATE-RGD;

[0075] like Figure 4 As shown, the [ 177 The radioactive HPLC spectrum of the labeling reaction solution of Lu]Lu-DOTA-TATE-RGD shows that [ 177 The radiochemical purity of Lu]Lu-DOTA-TATE-RGD was greater than 95%;

[0076] In the above steps, in the radio-HPLC determination, the first mobile phase is an aqueous solution of 0.1% trifluoroacetic acid, the second mobile phase is acetonitrile, and the gradient elution conditions are: 0 min, 95% of the first mobile phase; 0 to 20 min, 95% to 0% of the first mobile phase; the flow rate of the mobile phase is 1 mL / min.

[0077] Example 5: 68 Preparation of Ga]Ga-NOTA-TOC-RGD

[0078] A pure water solution (1 mg / mL) containing 10 nmol NOTA-TOC-RGD was mixed with 93 μL of 1.25 M sodium acetate solution to obtain a radioligand sodium acetate mixed solution; a germanium gallium generator (Eckert & Ziegler, 1850 MBq, 50 mCi) was eluted with 5 mL of 0.1 M high-purity hydrochloric acid solution to obtain [ 68Ga]GaCl3 hydrochloric acid solution, take 1mL, add it to the radioligand sodium acetate mixed solution, mix well, react at 90℃ for 7min, cool to room temperature, purify with C18 column, and determine its radiochemical purity with radio-HPLC to obtain [ 68 Ga]Ga-NOTA-TOC-RGD;

[0079] like Figure 5 As shown, it is prepared in Example 3 of the present invention [ 68 The radioactive HPLC spectrum of the labeled reaction solution of Ga]Ga-NOTA-TOC-RGD shows that [ 68 The radiochemical purity of Ga]Ga-NOTA-TOC-RGD is greater than 95%;

[0080] In the above steps, in the C18 column purification, 10 mL of ethanol and 10 mL of water are used to activate the C18 column. After the reaction solution is loaded onto the column, the column is rinsed with 10 mL of water and 0.3 mL of ethanol is used to elute the column to obtain the product;

[0081] In the above steps, in the radio-HPLC determination, the first mobile phase is an aqueous solution of 0.1% trifluoroacetic acid, the second mobile phase is acetonitrile, and the gradient elution conditions are: 0 min, 95% of the first mobile phase; 0 to 20 min, 95% to 0% of the first mobile phase; the flow rate of the mobile phase is 1 mL / min.

[0082] Application Example 1:

[0083] [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTA-RGDyk cellular uptake:

[0084] A549 cells were prepared at 1×10 6 Cell suspensions of 100 cells / mL were plated in 24-well plates, and 0.1 MBq of [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68Ga]Ga-DOTA-RGDyk solution was incubated at 37°C for 30, 60, and 120 min, and its uptake was terminated by using cold PBS solution. 1N NaOH solution was added to lyse the cells, and the radioactivity count of the lysate was measured;

[0085] like Figure 6 As shown, in the application example 1 of the present invention, the in vitro A549 cell uptake [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTA-RGDyk uptake-time curve (n=3);

[0086] The results of in vitro cell uptake experiments show that [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTA-RGDyk can be rapidly taken up by A549 cells and remain stable for 120 min. 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 The uptake of Ga]Ga-NOTA-TOC-RGD was higher than that of [ 68 Ga]Ga-DOTA-RGDyk increased.

[0087] Application Example 2:

[0088] [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTATATE Cellular Uptake:

[0089] HEK293-SSTR2 cells were prepared to 1×10 6 Cell suspensions of 100 cells / mL were plated in 24-well plates, and 0.1 MBq of [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTATATE solution was incubated at 37°C for 30, 60, and 120 min, and its uptake was terminated by using cold PBS solution. 1N NaOH solution was added to lyse the cells, and the radioactivity count of the lysate was measured;

[0090] like Figure 7 As shown, in the application example 2 of the present invention, HEK293-SSTR2 cells in vitro uptake [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTATATE uptake-time curve (n=3);

[0091] The results of in vitro cell uptake experiments show that [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD and [ 68 Ga]Ga-DOTATATE can be rapidly taken up by HEK293-SSTR2 cells and remain stable for 120 min. 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 The uptake of Ga]Ga-NOTA-TOC-RGD was higher than that of [ 68 Ga]Ga-DOTATATE was reduced.

[0092] Application Example 3:

[0093] [ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 Biodistribution experiment of Ga]Ga-NOTA-TOC-RGD:

[0094] After marking the end of [ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 Ga]Ga-NOTA-TOC-RGD solution was diluted with physiological saline and 50 μCi of the drug solution was injected into the tail vein of mice bearing A549 and H69 tumors. After 60 and 120 min, the mice were killed by cervical dislocation, and the tissues of interest were taken to measure the radioactivity counts;

[0095] like Figure 8 As shown, in the application example 3 of the present invention, injection [ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 After Ga]Ga-NOTA-TOC-RGD, [ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 Ga]Ga-NOTA-TOC-RGD had higher uptake in A549 or H69 tumors and was excreted through the renal system; compared with [ 68 Ga]Ga-NOTA-3PEG4-TATE-RGD, [ 68 The tumor uptake ability of Ga]Ga-DOTA-TATE-RGD was maintained, the renal uptake was reduced, and the T / B ratio was increased; 68 The H69 tumor uptake of Ga]Ga-NOTA-TOC-RGD was reduced.

[0096] Application Example 4:

[0097] [ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 In vivo PET imaging of Ga]Ga-NOTA-TOC-RGD tumor mice:

[0098] 3.7MBq[ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 Ga]Ga-NOTA-TOC-RGD isotonic solution was injected into A549 and H69 tumor-bearing mice via the tail vein. After 60 minutes, PET imaging was performed on the tumor mice in the prone position. 68 Ga]Ga-DOTA-RGDyk, [ 68 Ga]Ga-DOTATATE small animal PET imaging was used as a positive control;

[0099] like Fig. 9 As shown, in the application example 4 of the present invention, injection [ 68 Ga]Ga-DOTA-TATE-RGD and [ 68 PET imaging images of mice with Ga]Ga-NOTA-TOC-RGD tumors, 68 Ga]Ga-DOTA-TATE-RGD and [ 68 Ga]Ga-NOTA-TOC-RGD can be specifically taken up by tumors and excreted through the renal system.

[0100] In the present invention 68Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD can be specifically taken up by integrin receptor-positive cells and SSTR2-positive cells with high binding affinity; in vivo biodistribution studies in tumor mice and small animal PET imaging further showed that [ 68 Ga]Ga-DOTA-TATE-RGD, [ 177 Lu]Lu-DOTA-TATE-RGD, [ 68 Ga]Ga-NOTA-TOC-RGD has dual targeting capabilities for integrin receptors and SSTR2, among which [ 68 Ga]Ga-DOTA-TATE-RGD compared to [ 68 The renal uptake of Ga]Ga-NOTA-3PEG4-TATE-RGD was reduced and the T / B ratio was increased.

[0101] The radiolabeled α V The dual-targeting complex of β3 and SSTR2 contains different chelators and can chelate with almost all the radioactive metal nuclides currently used in clinical diagnosis and treatment, including β-emitting + X-rays for diagnosis 68 Ga, [ 18 F]AlF, 44 Sc and 64 Nuclides such as Cu; emit β - Radiation therapy 177 Lu and 90 Nuclides such as Y; emit alpha rays for treatment 225 Ac and 212 / 213 Bi and other radionuclides will help improve the detection rate of high-grade NET lesions, achieve more accurate tumor staging and disease prognosis, and are expected to be used in radionuclide targeted therapy.

[0102] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.

Claims

1. A radiolabeled α V β3 and SSTR2 dual-targeting complex, the general formula is as follows: in, Chelator is a chelating group or a chelating structure for chelating radionuclides, selected from any one of the following: Among them, M includes but is not limited to 68 Ga, 18 F-AlF, 177 Lu, 90 Y. 44 Sc, 225 Ac, 212 Pb, 213 Bi; L1 is a linker group connected to the integrin receptor, selected from any of the following: Wherein, n is an integer from 1 to 6; L2 is a connecting group between the SSTR2 targeting group and is selected from any one of the following: Wherein, n is an integer from 1 to 6; L3 is a connecting group with the chelating group or the chelating structure of the chelated radionuclide, selected from any one of the following: Wherein, n is an integer from 1 to 6; Peptide is a SSTR2 targeting group, selected from any one of the following: JR11, LM3, LM4, TATE, TOC, NOC, and has the following structure:

2. The radiolabeled α- V β3 and SSTR2 dual-targeting complex, characterized by: The radiolabeled α V The specific structure of the β3 and SSTR2 dual-targeting complex is as follows: M = 68 Ga or 177 Lu, [ 68 Ga / 177 Lu].

3. The radiolabeled α according to claim 1 V β3 and SSTR2 dual-targeting complex, characterized by: The radiolabeled α V The specific structure of the β3 and SSTR2 dual-targeting complex is as follows:

4. The radiolabeled α- V Application of β3 and SSTR2 dual-targeting complexes in high-grade NET imaging and radionuclide diagnosis.

5. The radiolabeled α V Application of β3 and SSTR2 dual-targeting complexes in the preparation of PRRT drugs.